A little light surfing today:
med.nyu.edu
"aggresomes"
the-scientist.com
--this happens to have Kopito in it, followed him
over from 'Biosynthesis and Degradation of CFTR'
proteasome.com
a better copy of the figure for printing
proteasome.com
oh my god, it is not so complicated, heh
This stuff rings a bell, here is something for
the Rigelites:
srinstitute.com
The Discovery and Development of E3 Ligase Inhibitors in Inflammation and Virology
--------------------------------------------------------------------------------
Date: Monday, June 21, 2004
Time: 4:15 PM to 4:45 PM
Place: Park Hyatt at the Bellevue
We have developed high throughput biochemical and cell based screens to examine the activity of the E3 ligase TRAF6, a critical signaling enzyme in the inflammation cascade initiated by Il-1. Various aspects of ligase HTS will be discussed, as well as follow up assays to determine selectivity and specificity in this enzyme class. Multiple functional cell based screens to monitor progress in the chemical SAR of several scaffold series will be presented. Parallel programs examining the role of E3 ligases in regulating HIV pathogenesis will also be presented. Just as kinase “friendly” scaffolds have led to the development of clinical candidates against that class of target, our efforts are focused on discovering and developing E3 ligase “friendly” inhibitors, that can form the foundation for developing a class of small molecule that can be evolved to target several members of this exciting new class of drug targets.
Donald Payan, Ph.D.
Chief Scientific Officer
RIGEL
Anyway, back to CF, I sold Rigel when it was
50% lower than where it is now, my bad.
Here is the patent which covers using that spice
for CF (I hope he has to package his tumeric or
whatever it is in little aav capsules, tee hee)
United States Patent Application 20030149113
Kind Code A1
Caplan, Michael J. ; et al. August 7, 2003
--------------------------------------------------------------------------------
Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
Abstract
This invention provides the methodology and agents for treating any disease or clinical condition which is at least partly the result of endoplasmic reticulum-associated retention of proteins. Thus, the methods and agents of the present invention provide for the release of normally retained proteins from the endoplasmic reticulum. The present invention is particularly useful for treating any disease or clinical condition which is at least partly the result of endoplasmic reticulum-associated retention or degradation of mis-assembled or mis-folded proteins.
I was looking at the tgen ITR patent, and had to
go here for some GT 101:
Commentary
Size does matter: overcoming the adeno-associated virus
packaging limit
Terence R Flotte
respiratory-research.com
This will take you to the Englehardt lab, and
possibly right back to reading about the proteasome again.
uiowa.edu
In a second strategy developed in Engelhardt's lab, and also licensed to Targeted Genetics Corporation, this disadvantageous tagging process can be disrupted, greatly increasing the efficiency by which AAV delivers its genes to the nucleus.
However, I did not intend to trip on ubiquitin, I was
merely spinning my wheels a bit today and having some
fun with google again. |
